Title	Sage Therapeutics Announces Second Quarter 2025 Financial Results
ID	12043415
External ID	7934556514
Author	Unknown
Published Date	July 30, 2025, 3:15 p.m.
Summary	Idag, 22:05 Ämnen i artikeln Idag, 22:05 Ämnen i artikeln Annons Annons Annons Annons Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second qu
Tags	None
URL	https://www.placera.se/pressmeddelanden/sage-therapeutics-sage-therapeutics-announces-second-quarter-2025-financial-results-20250730
Sentiment	Negative: 0.00848 Neutral: 0.23461 Positive: 0.75691
Relevance	0.01873

Content ID	7697812
Key	ab768743-8a14-4bc0-b49a-9edd8f0962db
Content	Idag, 22:05 Ämnen i artikeln Idag, 22:05 Ämnen i artikeln Annons Annons Annons Annons Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of helping more patients.” Second Quarter 2025 Highlights ZURZUVAE ZURZUVAE was approved by the FDA in August 2023 as the first-and-only oral treatment indicated for adults with postpartum depression (PPD). ZURZUVAE was made commercially available in the U.S. in December 2023. The current commercialization investment plan includes recent joint sales force expansions and marketing tactics intended to further accelerate ZURZUVAE growth in PPD, along with expanded disease state awareness efforts to support increased PPD screening and diagnosis. The Company anticipates these investments will help support the goal of significant topline revenue growth in 2025. As of the second quarter ended June 30, 2025, the following results had been achieved: In terms of prescriber, payer, and patient trends: SAGE-319 SAGE-319 is an extrasynaptic-preferring GABAA receptor positive allosteric modulator (PAM) designed to have novel pharmacology and a differentiated clinical profile from other GABAA receptor PAMs in our portfolio. It is currently being investigated as a potential treatment for behavioral symptoms associated with certain neurodevelopmental disorders. The Company expects data from a Phase 1 multiple ascending dose (MAD) study by late 2025 and will evaluate next steps based on these data. Pre-Clinical Pipeline The Company is continuing to explore targeted work within its NMDA receptor negative allosteric modulator (NAM) platform, focusing on potential treatments for neurodevelopmental disorders, with SAGE-817 and SAGE-039. Areas In Evaluation SAGE-324: The Company is evaluating potential indications, including seizures in developmental and epileptic encephalopathies (DEEs), and expects to provide an update on next steps, if any, in mid-2025. Business Update In June 2025, Sage and Supernus announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025. FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 Conference Call Information In light of the pending transaction with Supernus, Sage will not be hosting a conference call and webcast to review its second quarter 2025 financial results. About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at or engage with us on , and Forward-Looking Statements Various statements in this release concern Sage's future expectations, plans and prospects, including with respect to Sage, Supernus, the tender offer for outstanding shares of Sage common stock (the “Offer”), the merger of Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus with and into Sage, with Sage surviving as a wholly owned subsidiary of Supernus (the “Merger”), the Agreement and Plan of Merger, dated June 13, 2025, by and among Supernus, Purchaser, and Sage (the “Merger Agreement”) and the other transactions contemplated by the Merger Agreement (collectively, the “Transactions”). Forward-looking statements include, without limitation, our statements regarding: our plans, expectations and goals for commercialization of ZURZUVAE for the treatment of women with PPD, including our goals to establish ZURZUVAE as the standard of care for women with PPD and to advance care for women with PPD; our beliefs in the potential for ZURZUVAE, including that ZURZUVAE will be successful and gain market acceptance as a transformative treatment helping women with PPD and be instrumental in accelerating progress in maternal mental health; the ability of Sage and Supernus to satisfy the conditions to the consummation of the Offer and the other conditions to the consummation of the Merger; the anticipated timetable for closing of the Transactions; Sage's ability to commercialize current and future product candidates (including further commercialization of ZURZUVAE); our investment plans for ZURZUVAE and our expectations regarding the impact of increased investment, including recent joint sales force expansions and planned marketing tactics, in support of our goals to accelerate market growth in PPD; our plans for expanded disease state awareness efforts to support increased PPD screening and diagnosis; our plans and other goals related to other aspects of commercialization; anticipated timelines for our clinical development efforts, including the expected timing of readout of the multiple ascending dose study for SAGE-319; our belief in the potential profile and benefit of our product candidates, including potential indications for our product candidates; our plans to evaluate SAGE-324 in additional indications, including seizures in DEEs, and the timing of our announcement of next steps regarding the SAGE-324 program; our plans to explore targeted work within our NMDA receptor NAM platform with SAGE-817 and SAGE-039; and the mission and goals for our business. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: our commercialization efforts in the U.S. with respect to ZURZUVAE for the treatment of women with PPD may not be successful, and we may be unable to generate revenues from sales of ZURZUVAE at the levels or on the timing we expect or at levels or on the timing necessary to support our goals; the number of women with PPD, the unmet need for additional treatment options, and the potential market for ZURZUVAE for the treatment of women with PPD may be significantly smaller than we expect; early positive signs, including ZURZUVAE results in 2024 and the first two quarters of 2025, may not be a signal of future success; ZURZUVAE may not achieve, or even if achieved, maintain, the clinical benefit, clinical use or market acceptance for the treatment of PPD that we expect, including among OBGYNs, or we may encounter reimbursement, market access, process-related, or other issues, including competition in the market, or issues with our distribution network that impact the success of our commercialization efforts; ZURZUVAE may never become the standard of care for women with PPD; we may encounter delays in initiation, conduct, completion of enrollment or completion and reporting of data with respect to any of our ongoing studies or clinical trials, such as the completion of the multiple ascending dose study for SAGE-319, including as a result of slower than expected site initiation, slower than expected enrollment, the need or decision to expand the trials or other changes, that may impact our ability to meet our expected timelines and may increase our costs; unexpected concerns may arise from additional data, analysis or results from any of our completed studies; decisions or actions of the FDA or the timing of meetings with the FDA may affect the timing, design, size, progress, and cost of clinical trials or the timing of data readouts or our ability to proceed with further development or may impair the potential for successful development or the timing or success of filing for and gaining regulatory approval; we may encounter adverse events at any stage that negatively impact further development and the potential for approval of our product candidates or the potential for successful commercialization of any of our products or that require additional non-clinical and clinical work, which may not yield positive results; the need to align with our collaborators may hamper or delay our development and commercialization efforts for the products or product candidates that are part of the collaboration or increase our costs; the anticipated benefits of our ongoing collaborations, including the receipt of payments or the successful development or commercialization of products and generation of revenue, may never be achieved at the levels or timing we expect or at all; our business may be adversely affected and our costs may increase if any of our key collaborators fails to perform its obligations or terminates our collaboration; the internal and external costs required for our ongoing, planned, and other future activities, and the resulting impact on expenses and use of cash, may be higher than expected, which may cause us to use cash quicker than expected or change or curtail some of our plans or both; our expectations as to expenses, cash usage, potential revenue, funding from collaborations, including milestones, cash runway, and cash needs may prove not to be correct for other reasons, such as changes in plans or actual events being different than our assumptions; we may not be successful in our efforts to gain regulatory approval of products beyond ZURZUVAE; we may not achieve revenues from our products that may be successfully developed in the future at levels we expect; the various closing conditions for the Transactions may not be satisfied or waived; the Transactions may negatively impact relationships with employees, other business partners, or governmental entities; Supernus may not realize the potential benefits of the Transactions; any of the foregoing events could impair the drivers and value creation opportunities for our business; and we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates or the commercialization of any current or future marketed product, which may delay our timing or change our plans, increase our costs or otherwise negatively impact our business; as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent annual or quarterly report filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. Financial Tables Sage Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands) (unaudited) June 30, 2025 December 31, 2024 Cash, cash equivalents and marketable securities Total assets Total liabilities Total stockholders' equity Sage Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, Product revenue, net Collaboration revenue - related party Other collaboration revenue Total revenues Operating costs and expenses: Cost of revenues Research and development Selling, general and administrative Restructuring Total operating costs and expenses Loss from operations Interest income Other income (expense), net Net loss Net loss per share - basic and diluted Weighted average shares outstanding - basic and diluted SELECT IMPORTANT SAFETY INFORMATION FOR ZURZUVAE ZURZUVAE (zuranolone) CIV, is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression in adults. This does not include all the information needed to use ZURZUVAE safely and effectively. See full prescribing information for ZURZUVAE. ZURZUVAE may cause serious side effects, including decreased awareness and alertness, which can affect your ability to drive safely or safely do other dangerous activities. Do not drive, operate machinery, or do other dangerous activities until at least 12 hours after taking each dose. You may not be able to tell on your own if you can drive safely or tell how much ZURZUVAE is affecting you. ZURZUVAE may cause central nervous system (CNS) depressant effects including sleepiness, drowsiness, slow thinking, dizziness, confusion, and trouble walking. Taking alcohol, other medicines that cause CNS depressant effects such as benzodiazepines, or opioids while taking ZURZUVAE can make these symptoms worse and may also cause trouble breathing. ZURZUVAE is a federally controlled substance schedule IV because it contains zuranolone, which can be abused or lead to dependence. Tell your healthcare provider right away if you become pregnant or plan to become pregnant during treatment with ZURZUVAE. You should use effective birth control (contraception) during treatment with ZURZUVAE and for 1 week after the final dose. ZURZUVAE and other antidepressant medicines may increase the risk of suicidal thoughts and actions in people 24 years of age and younger. ZURZUVAE is not for use in children. The most common side effects of ZURZUVAE include sleepiness or drowsiness, dizziness, common cold, diarrhea, feeling tired, weak, or having no energy, and urinary tract infection. View source version on businesswire.com: Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of helping more patients.” Second Quarter 2025 Highlights ZURZUVAE ZURZUVAE was approved by the FDA in August 2023 as the first-and-only oral treatment indicated for adults with postpartum depression (PPD). ZURZUVAE was made commercially available in the U.S. in December 2023. The current commercialization investment plan includes recent joint sales force expansions and marketing tactics intended to further accelerate ZURZUVAE growth in PPD, along with expanded disease state awareness efforts to support increased PPD screening and diagnosis. The Company anticipates these investments will help support the goal of significant topline revenue growth in 2025. As of the second quarter ended June 30, 2025, the following results had been achieved: In terms of prescriber, payer, and patient trends: SAGE-319 SAGE-319 is an extrasynaptic-preferring GABAA receptor positive allosteric modulator (PAM) designed to have novel pharmacology and a differentiated clinical profile from other GABAA receptor PAMs in our portfolio. It is currently being investigated as a potential treatment for behavioral symptoms associated with certain neurodevelopmental disorders. The Company expects data from a Phase 1 multiple ascending dose (MAD) study by late 2025 and will evaluate next steps based on these data. Pre-Clinical Pipeline The Company is continuing to explore targeted work within its NMDA receptor negative allosteric modulator (NAM) platform, focusing on potential treatments for neurodevelopmental disorders, with SAGE-817 and SAGE-039. Areas In Evaluation SAGE-324: The Company is evaluating potential indications, including seizures in developmental and epileptic encephalopathies (DEEs), and expects to provide an update on next steps, if any, in mid-2025. Business Update In June 2025, Sage and Supernus announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025. FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 Conference Call Information In light of the pending transaction with Supernus, Sage will not be hosting a conference call and webcast to review its second quarter 2025 financial results. About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at or engage with us on , and Forward-Looking Statements Various statements in this release concern Sage's future expectations, plans and prospects, including with respect to Sage, Supernus, the tender offer for outstanding shares of Sage common stock (the “Offer”), the merger of Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus with and into Sage, with Sage surviving as a wholly owned subsidiary of Supernus (the “Merger”), the Agreement and Plan of Merger, dated June 13, 2025, by and among Supernus, Purchaser, and Sage (the “Merger Agreement”) and the other transactions contemplated by the Merger Agreement (collectively, the “Transactions”). Forward-looking statements include, without limitation, our statements regarding: our plans, expectations and goals for commercialization of ZURZUVAE for the treatment of women with PPD, including our goals to establish ZURZUVAE as the standard of care for women with PPD and to advance care for women with PPD; our beliefs in the potential for ZURZUVAE, including that ZURZUVAE will be successful and gain market acceptance as a transformative treatment helping women with PPD and be instrumental in accelerating progress in maternal mental health; the ability of Sage and Supernus to satisfy the conditions to the consummation of the Offer and the other conditions to the consummation of the Merger; the anticipated timetable for closing of the Transactions; Sage's ability to commercialize current and future product candidates (including further commercialization of ZURZUVAE); our investment plans for ZURZUVAE and our expectations regarding the impact of increased investment, including recent joint sales force expansions and planned marketing tactics, in support of our goals to accelerate market growth in PPD; our plans for expanded disease state awareness efforts to support increased PPD screening and diagnosis; our plans and other goals related to other aspects of commercialization; anticipated timelines for our clinical development efforts, including the expected timing of readout of the multiple ascending dose study for SAGE-319; our belief in the potential profile and benefit of our product candidates, including potential indications for our product candidates; our plans to evaluate SAGE-324 in additional indications, including seizures in DEEs, and the timing of our announcement of next steps regarding the SAGE-324 program; our plans to explore targeted work within our NMDA receptor NAM platform with SAGE-817 and SAGE-039; and the mission and goals for our business. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: our commercialization efforts in the U.S. with respect to ZURZUVAE for the treatment of women with PPD may not be successful, and we may be unable to generate revenues from sales of ZURZUVAE at the levels or on the timing we expect or at levels or on the timing necessary to support our goals; the number of women with PPD, the unmet need for additional treatment options, and the potential market for ZURZUVAE for the treatment of women with PPD may be significantly smaller than we expect; early positive signs, including ZURZUVAE results in 2024 and the first two quarters of 2025, may not be a signal of future success; ZURZUVAE may not achieve, or even if achieved, maintain, the clinical benefit, clinical use or market acceptance for the treatment of PPD that we expect, including among OBGYNs, or we may encounter reimbursement, market access, process-related, or other issues, including competition in the market, or issues with our distribution network that impact the success of our commercialization efforts; ZURZUVAE may never become the standard of care for women with PPD; we may encounter delays in initiation, conduct, completion of enrollment or completion and reporting of data with respect to any of our ongoing studies or clinical trials, such as the completion of the multiple ascending dose study for SAGE-319, including as a result of slower than expected site initiation, slower than expected enrollment, the need or decision to expand the trials or other changes, that may impact our ability to meet our expected timelines and may increase our costs; unexpected concerns may arise from additional data, analysis or results from any of our completed studies; decisions or actions of the FDA or the timing of meetings with the FDA may affect the timing, design, size, progress, and cost of clinical trials or the timing of data readouts or our ability to proceed with further development or may impair the potential for successful development or the timing or success of filing for and gaining regulatory approval; we may encounter adverse events at any stage that negatively impact further development and the potential for approval of our product candidates or the potential for successful commercialization of any of our products or that require additional non-clinical and clinical work, which may not yield positive results; the need to align with our collaborators may hamper or delay our development and commercialization efforts for the products or product candidates that are part of the collaboration or increase our costs; the anticipated benefits of our ongoing collaborations, including the receipt of payments or the successful development or commercialization of products and generation of revenue, may never be achieved at the levels or timing we expect or at all; our business may be adversely affected and our costs may increase if any of our key collaborators fails to perform its obligations or terminates our collaboration; the internal and external costs required for our ongoing, planned, and other future activities, and the resulting impact on expenses and use of cash, may be higher than expected, which may cause us to use cash quicker than expected or change or curtail some of our plans or both; our expectations as to expenses, cash usage, potential revenue, funding from collaborations, including milestones, cash runway, and cash needs may prove not to be correct for other reasons, such as changes in plans or actual events being different than our assumptions; we may not be successful in our efforts to gain regulatory approval of products beyond ZURZUVAE; we may not achieve revenues from our products that may be successfully developed in the future at levels we expect; the various closing conditions for the Transactions may not be satisfied or waived; the Transactions may negatively impact relationships with employees, other business partners, or governmental entities; Supernus may not realize the potential benefits of the Transactions; any of the foregoing events could impair the drivers and value creation opportunities for our business; and we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates or the commercialization of any current or future marketed product, which may delay our timing or change our plans, increase our costs or otherwise negatively impact our business; as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent annual or quarterly report filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. Financial Tables Sage Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands) (unaudited) June 30, 2025 December 31, 2024 Cash, cash equivalents and marketable securities Total assets Total liabilities Total stockholders' equity Sage Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, Product revenue, net Collaboration revenue - related party Other collaboration revenue Total revenues Operating costs and expenses: Cost of revenues Research and development Selling, general and administrative Restructuring Total operating costs and expenses Loss from operations Interest income Other income (expense), net Net loss Net loss per share - basic and diluted Weighted average shares outstanding - basic and diluted SELECT IMPORTANT SAFETY INFORMATION FOR ZURZUVAE ZURZUVAE (zuranolone) CIV, is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression in adults. This does not include all the information needed to use ZURZUVAE safely and effectively. See full prescribing information for ZURZUVAE. ZURZUVAE may cause serious side effects, including decreased awareness and alertness, which can affect your ability to drive safely or safely do other dangerous activities. Do not drive, operate machinery, or do other dangerous activities until at least 12 hours after taking each dose. You may not be able to tell on your own if you can drive safely or tell how much ZURZUVAE is affecting you. ZURZUVAE may cause central nervous system (CNS) depressant effects including sleepiness, drowsiness, slow thinking, dizziness, confusion, and trouble walking. Taking alcohol, other medicines that cause CNS depressant effects such as benzodiazepines, or opioids while taking ZURZUVAE can make these symptoms worse and may also cause trouble breathing. ZURZUVAE is a federally controlled substance schedule IV because it contains zuranolone, which can be abused or lead to dependence. Tell your healthcare provider right away if you become pregnant or plan to become pregnant during treatment with ZURZUVAE. You should use effective birth control (contraception) during treatment with ZURZUVAE and for 1 week after the final dose. ZURZUVAE and other antidepressant medicines may increase the risk of suicidal thoughts and actions in people 24 years of age and younger. ZURZUVAE is not for use in children. The most common side effects of ZURZUVAE include sleepiness or drowsiness, dizziness, common cold, diarrhea, feeling tired, weak, or having no energy, and urinary tract infection. View source version on businesswire.com:
Content Reference URL	None

Publisher Name	Avanza (#3174)
Publisher URL	https://www.placera.se
Description	None
Trust Flow Score	0
Citation Flow Score	21

Data Source Name	Quantexa News (#5)
Data Source Type	news
Data Source URL	https://app.aylien.com/dashboard
Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
Weight	10

DJDT

Versions

Package	Name	Version
Django		5.2.1
Python		3.11.8
coverage	Coverage	7.4.4
debug_toolbar	Debug Toolbar	4.3.0
django_extensions	Django Extensions	5.2.1
grappelli	Grappelli	4.0.2

Time

Resource usage

Resource	Value
User CPU time	52.764 msec
System CPU time	4.232 msec
Total CPU time	56.996 msec
Elapsed time	81.682 msec
Context switches	13 voluntary, 2 involuntary

Browser timing

Timing attribute	Timeline	Milliseconds since navigation start (+length)

Settings from app.settings

Setting	Value
ABSOLUTE_URL_OVERRIDES	`{}`
ADMINS	`[]`
ALLOWED_HOSTS	`['*']`
APPEND_SLASH	`True`
AUTH0_CLIENT_ID	`'********************'`
AUTH0_CLIENT_SECRET	`'********************'`
AUTH0_DOMAIN	`'********************'`
AUTHENTICATION_BACKENDS	`'********************'`
AUTH_PASSWORD_VALIDATORS	`'********************'`
AUTH_USER_MODEL	`'********************'`
BASE_DIR	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe')`
CACHES	`{'default': {'BACKEND': 'django.core.cache.backends.filebased.FileBasedCache', 'LOCATION': '/var/tmp/django_cache'}}`
CACHE_MIDDLEWARE_ALIAS	`'default'`
CACHE_MIDDLEWARE_KEY_PREFIX	`'********************'`
CACHE_MIDDLEWARE_SECONDS	`600`
CELERY_BROKER_URL	`'redis://localhost:6379'`
CELERY_RESULT_BACKEND	`'redis://localhost:6379'`
CSRF_COOKIE_AGE	`31449600`
CSRF_COOKIE_DOMAIN	`None`
CSRF_COOKIE_HTTPONLY	`False`
CSRF_COOKIE_NAME	`'csrftoken'`
CSRF_COOKIE_PATH	`'/'`
CSRF_COOKIE_SAMESITE	`'Lax'`
CSRF_COOKIE_SECURE	`False`
CSRF_FAILURE_VIEW	`'django.views.csrf.csrf_failure'`
CSRF_HEADER_NAME	`'HTTP_X_CSRFTOKEN'`
CSRF_TRUSTED_ORIGINS	`[]`
CSRF_USE_SESSIONS	`False`
DATABASES	`{'default': {'ATOMIC_REQUESTS': False, 'AUTOCOMMIT': True, 'CONN_HEALTH_CHECKS': False, 'CONN_MAX_AGE': 0, 'ENGINE': 'django.db.backends.postgresql', 'HOST': '34.125.28.12', 'NAME': 'pennyloupe', 'OPTIONS': {}, 'PASSWORD': '********************', 'PORT': '5432', 'TEST': {'CHARSET': None, 'COLLATION': None, 'MIGRATE': True, 'MIRROR': None, 'NAME': None}, 'TIME_ZONE': None, 'USER': 'pennyloupe'}}`
DATABASE_ROUTERS	`[]`
DATA_UPLOAD_MAX_MEMORY_SIZE	`2621440`
DATA_UPLOAD_MAX_NUMBER_FIELDS	`1000`
DATA_UPLOAD_MAX_NUMBER_FILES	`100`
DATETIME_FORMAT	`'N j, Y, P'`
DATETIME_INPUT_FORMATS	`['%Y-%m-%d %H:%M:%S', '%Y-%m-%d %H:%M:%S.%f', '%Y-%m-%d %H:%M', '%m/%d/%Y %H:%M:%S', '%m/%d/%Y %H:%M:%S.%f', '%m/%d/%Y %H:%M', '%m/%d/%y %H:%M:%S', '%m/%d/%y %H:%M:%S.%f', '%m/%d/%y %H:%M']`
DATE_FORMAT	`'N j, Y'`
DATE_INPUT_FORMATS	`['%Y-%m-%d', '%m/%d/%Y', '%m/%d/%y', '%b %d %Y', '%b %d, %Y', '%d %b %Y', '%d %b, %Y', '%B %d %Y', '%B %d, %Y', '%d %B %Y', '%d %B, %Y']`
DEBUG	`True`
DEBUG_PROPAGATE_EXCEPTIONS	`False`
DEBUG_TOOLBAR_CONFIG	`{'SHOW_TOOLBAR_CALLBACK': <function <lambda> at 0x7f3fcd3ef1a0>}`
DECIMAL_SEPARATOR	`'.'`
DEFAULT_AUTO_FIELD	`'django.db.models.BigAutoField'`
DEFAULT_CHARSET	`'utf-8'`
DEFAULT_EXCEPTION_REPORTER	`'django.views.debug.ExceptionReporter'`
DEFAULT_EXCEPTION_REPORTER_FILTER	`'django.views.debug.SafeExceptionReporterFilter'`
DEFAULT_FROM_EMAIL	`'webmaster@localhost'`
DEFAULT_INDEX_TABLESPACE	`''`
DEFAULT_TABLESPACE	`''`
DISALLOWED_USER_AGENTS	`[]`
EMAIL_BACKEND	`'django.core.mail.backends.smtp.EmailBackend'`
EMAIL_HOST	`'localhost'`
EMAIL_HOST_PASSWORD	`'********************'`
EMAIL_HOST_USER	`''`
EMAIL_PORT	`25`
EMAIL_SSL_CERTFILE	`None`
EMAIL_SSL_KEYFILE	`'********************'`
EMAIL_SUBJECT_PREFIX	`'[Django] '`
EMAIL_TIMEOUT	`None`
EMAIL_USE_LOCALTIME	`False`
EMAIL_USE_SSL	`False`
EMAIL_USE_TLS	`False`
FIELD_ENCRYPTION_KEY	`'********************'`
FILE_UPLOAD_DIRECTORY_PERMISSIONS	`None`
FILE_UPLOAD_HANDLERS	`['django.core.files.uploadhandler.MemoryFileUploadHandler', 'django.core.files.uploadhandler.TemporaryFileUploadHandler']`
FILE_UPLOAD_MAX_MEMORY_SIZE	`2621440`
FILE_UPLOAD_PERMISSIONS	`420`
FILE_UPLOAD_TEMP_DIR	`None`
FIRST_DAY_OF_WEEK	`0`
FIXTURE_DIRS	`[]`
FORCE_SCRIPT_NAME	`None`
FORMAT_MODULE_PATH	`None`
FORMS_URLFIELD_ASSUME_HTTPS	`False`
FORM_RENDERER	`'django.forms.renderers.DjangoTemplates'`
GCP_LOCATION	`'us-central1'`
GCP_PROJECT_ID	`'advance-honor-411011'`
GCP_PROJECT_NUMBER	`'268856636042'`
GCP_SERVICE_ACCOUNT	`'/Users/kcallahan/.config/gcloud/vector-search-user.json'`
GCP_VERTEX_BUCKET	`'pennyloupe-us-central1'`
GCP_VERTEX_INDEX_ID	`'2477861603379249152'`
GRAPPELLI_ADMIN_TITLE	`'Penny Loupe'`
GRAPPELLI_AUTOCOMPLETE_SEARCH_FIELDS	`{'auth': '********************'}`
IGNORABLE_404_URLS	`[]`
INSTALLED_APPS	`['coverage', 'grappelli', 'django.contrib.admin', 'django.contrib.auth', 'django.contrib.contenttypes', 'django.contrib.humanize', 'django.contrib.messages', 'django.contrib.postgres', 'django.contrib.sessions', 'django.contrib.staticfiles', 'django_htmx', 'app.core.apps.CoreConfig', 'django_extensions', 'debug_toolbar']`
INTERNAL_IPS	`['127.0.0.1']`
LANGUAGES	`[('en', 'English')]`
LANGUAGES_BIDI	`['he', 'ar', 'ar-dz', 'ckb', 'fa', 'ug', 'ur']`
LANGUAGE_CODE	`'en-us'`
LANGUAGE_COOKIE_AGE	`None`
LANGUAGE_COOKIE_DOMAIN	`None`
LANGUAGE_COOKIE_HTTPONLY	`False`
LANGUAGE_COOKIE_NAME	`'django_language'`
LANGUAGE_COOKIE_PATH	`'/'`
LANGUAGE_COOKIE_SAMESITE	`None`
LANGUAGE_COOKIE_SECURE	`False`
LOCALE_PATHS	`[]`
LOGGING	`{}`
LOGGING_CONFIG	`'logging.config.dictConfig'`
LOGIN_REDIRECT_URL	`'/accounts/profile/'`
LOGIN_URL	`'/accounts/login/'`
LOGOUT_REDIRECT_URL	`None`
MANAGERS	`[]`
MEDIA_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/media')`
MEDIA_URL	`'/media/'`
MESSAGE_STORAGE	`'django.contrib.messages.storage.fallback.FallbackStorage'`
MIDDLEWARE	['django.middleware.security.SecurityMiddleware', 'whitenoise.middleware.WhiteNoiseMiddleware', 'django.contrib.sessions.middleware.SessionMiddleware', 'django.middleware.cache.UpdateCacheMiddleware', 'django.middleware.common.CommonMiddleware', 'django.middleware.csrf.CsrfViewMiddleware', 'django.contrib.auth.middleware.AuthenticationMiddleware', 'django.contrib.messages.middleware.MessageMiddleware', 'django.middleware.clickjacking.XFrameOptionsMiddleware', 'django_htmx.middleware.HtmxMiddleware', 'debug_toolbar.middleware.DebugToolbarMiddleware']
MIGRATION_MODULES	`{}`
MONTH_DAY_FORMAT	`'F j'`
NUMBER_GROUPING	`0`
OPENAI_API_KEY	`'********************'`
PASSWORD_HASHERS	`'********************'`
PASSWORD_RESET_TIMEOUT	`'********************'`
POLYGON_API_KEY	`'********************'`
PREPEND_WWW	`False`
QT_API_KEY	`'********************'`
QT_APP_ID	`'13d3cbab'`
QT_PASSWORD	`'********************'`
QT_USERNAME	`'kevin+dev3@pennyloupe.com'`
ROOT_URLCONF	`'app.urls'`
SALT_KEY	`'********************'`
SCRAPER_API_KEY	`'********************'`
SECRET_KEY	`'********************'`
SECRET_KEY_FALLBACKS	`'********************'`
SECURE_CONTENT_TYPE_NOSNIFF	`True`
SECURE_CROSS_ORIGIN_OPENER_POLICY	`'same-origin'`
SECURE_HSTS_INCLUDE_SUBDOMAINS	`False`
SECURE_HSTS_PRELOAD	`False`
SECURE_HSTS_SECONDS	`0`
SECURE_PROXY_SSL_HEADER	`None`
SECURE_REDIRECT_EXEMPT	`[]`
SECURE_REFERRER_POLICY	`'same-origin'`
SECURE_SSL_HOST	`None`
SECURE_SSL_REDIRECT	`False`
SERVER_EMAIL	`'root@localhost'`
SESSION_CACHE_ALIAS	`'default'`
SESSION_COOKIE_AGE	`1209600`
SESSION_COOKIE_DOMAIN	`None`
SESSION_COOKIE_HTTPONLY	`True`
SESSION_COOKIE_NAME	`'sessionid'`
SESSION_COOKIE_PATH	`'/'`
SESSION_COOKIE_SAMESITE	`'Lax'`
SESSION_COOKIE_SECURE	`False`
SESSION_ENGINE	`'django.contrib.sessions.backends.db'`
SESSION_EXPIRE_AT_BROWSER_CLOSE	`False`
SESSION_FILE_PATH	`None`
SESSION_SAVE_EVERY_REQUEST	`False`
SESSION_SERIALIZER	`'django.contrib.sessions.serializers.JSONSerializer'`
SETTINGS_MODULE	`'app.settings'`
SHORT_DATETIME_FORMAT	`'m/d/Y P'`
SHORT_DATE_FORMAT	`'m/d/Y'`
SIGNING_BACKEND	`'django.core.signing.TimestampSigner'`
SILENCED_SYSTEM_CHECKS	`[]`
SQL_FILES_DIR	`'/mnt/disks/pennyloupe_disk/pennyloupe/app/core/sql'`
STATICFILES_DIRS	`[]`
STATICFILES_FINDERS	`['django.contrib.staticfiles.finders.FileSystemFinder', 'django.contrib.staticfiles.finders.AppDirectoriesFinder']`
STATIC_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/static')`
STATIC_URL	`'/static/'`
STORAGES	`{'default': {'BACKEND': 'django.core.files.storage.FileSystemStorage'}, 'staticfiles': {'BACKEND': 'django.contrib.staticfiles.storage.StaticFilesStorage'}}`
TEMPLATES	`[{'APP_DIRS': True, 'BACKEND': 'django.template.backends.django.DjangoTemplates', 'DIRS': ['templates'], 'OPTIONS': {'context_processors': ['django.template.context_processors.debug', 'django.template.context_processors.request', 'django.contrib.auth.context_processors.auth', 'django.contrib.messages.context_processors.messages']}}]`
TEST_NON_SERIALIZED_APPS	`[]`
TEST_RUNNER	`'django.test.runner.DiscoverRunner'`
THOUSAND_SEPARATOR	`','`
TIME_FORMAT	`'P'`
TIME_INPUT_FORMATS	`['%H:%M:%S', '%H:%M:%S.%f', '%H:%M']`
TIME_ZONE	`'UTC'`
USE_I18N	`True`
USE_THOUSAND_SEPARATOR	`False`
USE_TZ	`True`
USE_X_FORWARDED_HOST	`False`
USE_X_FORWARDED_PORT	`False`
WSGI_APPLICATION	`'app.wsgi.application'`
X_FRAME_OPTIONS	`'DENY'`
YEAR_MONTH_FORMAT	`'F Y'`

Headers

Request headers

Key	Value
Accept	/
Accept-Encoding	gzip, br, zstd, deflate
Host	pennyloupe.com
User-Agent	Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Response headers

Key	Value
Content-Type	text/html; charset=utf-8

WSGI environ

Since the WSGI environ inherits the environment of the server, only a significant subset is shown below.

Key	Value
CONTENT_LENGTH
CONTENT_TYPE
PATH_INFO	/ticker/SAGE/content/12043415
QUERY_STRING
REMOTE_ADDR	216.73.216.112
REQUEST_METHOD	GET
SCRIPT_NAME
SERVER_NAME	pennyloupe.com
SERVER_PORT	443
SERVER_PROTOCOL	HTTP/1.1

Request

View information

View function	Arguments	Keyword arguments	URL name
`app.core.views.app.ticker_content_detail`	`()`	`{'content_id': 12043415, 'ticker': 'SAGE'}`	`ticker_content_detail`

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

default 12.12 ms (5 queries )

Query Timeline Time (ms) Action

SELECT "pl_content"."created_dt",
       "pl_content"."updated_dt",
       "pl_content"."status_id",
       "pl_content"."id",
       "pl_content"."key",
       "pl_content"."fetch_ref_id",
       "pl_content"."ticker",
       "pl_content"."publish_dt",
       "pl_content"."external_id",
       "pl_content"."published_by",
       "pl_content"."title",
       "pl_content"."summary",
       "pl_content"."tags",
       "pl_content"."url",
       "pl_content"."author",
       "pl_content"."author_reputation_score",
       "pl_content"."content_length",
       "pl_content"."parent_key",
       "pl_content"."sentiment_positive",
       "pl_content"."sentiment_negative",
       "pl_content"."sentiment_neutral",
       "pl_content"."sentiment",
       "pl_content"."sentiment_status",
       "pl_content"."relevance_score",
       "pl_content"."votes_positive",
       "pl_content"."votes_negative",
       "pl_content"."is_processing_flag",
       "pl_content"."vector_embedding_dt",
       "pl_content"."vector_id",
       "pl_content"."vector_status",
       "pl_content"."data_source_id",
       "pl_content"."parent_content_id",
       "pl_content"."publisher_id"
  FROM "pl_content"
WHERE "pl_content"."id" = 12043415
LIMIT 21SELECT ••• FROM "pl_content" WHERE "pl_content"."id" = 12043415 LIMIT 21

3.18

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2297)
  content = Content.objects.get(id=content_id)

SELECT "pl_content_content"."created_dt",
       "pl_content_content"."updated_dt",
       "pl_content_content"."status_id",
       "pl_content_content"."id",
       "pl_content_content"."key",
       "pl_content_content"."content",
       "pl_content_content"."content_ref_url",
       "pl_content_content"."content_id"
  FROM "pl_content_content"
WHERE "pl_content_content"."content_id" = 12043415
ORDER BY "pl_content_content"."id" ASC
LIMIT 1SELECT ••• FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 12043415 ORDER BY "pl_content_content"."id" ASC LIMIT 1

5.48

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2303)
  content_content = ContentContent.objects.filter(details=content).first()

SELECT "pl_content_publisher"."created_dt",
       "pl_content_publisher"."updated_dt",
       "pl_content_publisher"."status_id",
       "pl_content_publisher"."id",
       "pl_content_publisher"."name",
       "pl_content_publisher"."url",
       "pl_content_publisher"."domain",
       "pl_content_publisher"."description",
       "pl_content_publisher"."weight",
       "pl_content_publisher"."trust_flow_score",
       "pl_content_publisher"."citation_flow_score"
  FROM "pl_content_publisher"
WHERE "pl_content_publisher"."id" = 3174
LIMIT 21SELECT ••• FROM "pl_content_publisher" WHERE "pl_content_publisher"."id" = 3174 LIMIT 21

1.28

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2306)
  publisher = content.publisher

SELECT "pl_data_source"."created_dt",
       "pl_data_source"."updated_dt",
       "pl_data_source"."status_id",
       "pl_data_source"."id",
       "pl_data_source"."name",
       "pl_data_source"."type",
       "pl_data_source"."url",
       "pl_data_source"."description",
       "pl_data_source"."weight",
       "pl_data_source"."class_name",
       "pl_data_source"."class_params_json"
  FROM "pl_data_source"
WHERE "pl_data_source"."id" = 5
LIMIT 21SELECT ••• FROM "pl_data_source" WHERE "pl_data_source"."id" = 5 LIMIT 21

1.13

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2307)
  data_source = content.data_source

SELECT COUNT(*) AS "__count"
FROM "pl_content"
WHERE "pl_content"."parent_content_id" = 12043415SELECT COUNT(*) AS "__count" FROM "pl_content" WHERE "pl_content"."parent_content_id" = 12043415

1.04

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2319)
  return render(request, "ticker_content_detail.html", context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/shortcuts.py in render(25)
  content = loader.render_to_string(template_name, context, request, using=using)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader.py in render_to_string(62)
  return template.render(context, request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/backends/django.py in render(107)
  return self.template.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(171)
  return self._render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/test/utils.py in instrumented_test_render(114)
  return self.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader_tags.py in render(159)
  return compiled_parent._render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/test/utils.py in instrumented_test_render(114)
  return self.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader_tags.py in render(65)
  result = block.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/defaulttags.py in render(320)
  match = condition.eval(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/smartif.py in eval(61)
  return func(context, self.first, self.second)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/smartif.py in <lambda>(107)
  ">": infix(10, lambda context, x, y: x.eval(context) > y.eval(context)),

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/defaulttags.py in eval(886)
  return self.value.resolve(context, ignore_failures=True)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in resolve(722)
  obj = self.var.resolve(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in resolve(854)
  value = self._resolve_lookup(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in _resolve_lookup(925)
  current = current()

27	`<td><a href="{% url 'ticker_content_detail' ticker=ticker content_id=content_detail.content.parent.id %}">{{ content_detail.content.parent.title }}</a></td>`
28	`</tr>`
29	`{% endif %}`
30	`{% if content_detail.content.children.count > 0 %}`
31	`<tr>`
32	`<th>Children</th>`
33	`<td>`
34	`<ul>`

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html

Static files (720 found, 2 used)

Static file paths

None

Static file apps

grappelli
django.contrib.admin
django_htmx
app.core
django_extensions
debug_toolbar

Static files

css/pennyloupe.css: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/css/pennyloupe.css
img/penny_loupe_logo.png: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/img/penny_loupe_logo.png

django.contrib.staticfiles.finders.AppDirectoriesFinder (720 files)

Templates (6 rendered)

Template path

templates

Templates

ticker_content_detail.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb55b1300>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55b1080>>'} {'content_detail': {'content': <Content: Sage Therapeutics Announces Second Quarter 2025 Financial Results - Unknown>, 'content_content': <ContentContent: Content ID: 7697812>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: Avanza>}, 'ticker': 'SAGE'}
base.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/base.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb55b1300>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55b1080>>'} {'content_detail': {'content': <Content: Sage Therapeutics Announces Second Quarter 2025 Financial Results - Unknown>, 'content_content': <ContentContent: Content ID: 7697812>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: Avanza>}, 'ticker': 'SAGE'}
components/leftnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/leftnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb55b1300>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55b1080>>'} {'content_detail': {'content': <Content: Sage Therapeutics Announces Second Quarter 2025 Financial Results - Unknown>, 'content_content': <ContentContent: Content ID: 7697812>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: Avanza>}, 'ticker': 'SAGE'} {'block': <Block Node: leftnav. Contents: [<TextNode: '\n <div'>, <IncludeNode: template=<FilterExpression '"components/leftnav.html"'>>, <TextNode: '\n </di'>]>}
components/header.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/header.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb55b1300>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55b1080>>'} {'content_detail': {'content': <Content: Sage Therapeutics Announces Second Quarter 2025 Financial Results - Unknown>, 'content_content': <ContentContent: Content ID: 7697812>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: Avanza>}, 'ticker': 'SAGE'} {'block': <Block Node: header. Contents: [<TextNode: '\n\n '>, <IncludeNode: template=<FilterExpression '"components/header.html"'>>, <TextNode: '\n\n '>]>}
components/ticker_subnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/components/ticker_subnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb55b1300>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55b1080>>'} {'content_detail': {'content': <Content: Sage Therapeutics Announces Second Quarter 2025 Financial Results - Unknown>, 'content_content': <ContentContent: Content ID: 7697812>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: Avanza>}, 'ticker': 'SAGE'} {'block': <Block Node: content. Contents: [<TextNode: '\n\n <div class="uk-flex'>, <IncludeNode: template=<FilterExpression '"components/ticker_subnav.html"'>>, <TextNode: '\n <!-- /SUB NAV--'>, <Variable Node: content_detail.content.title>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.external_id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.author>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.publish_dt>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.summary>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.tags>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.sentiment_negative>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '<br/>\n '>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb618c5d0>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb618e710>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb617b150>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.relevance_score>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n <li clas'>, <Variable Node: content_detail.data_source.name>, <TextNode: '\n '>, <Variable Node: content_detail.data_source.id>, <TextNode: ')\n '>, <Variable Node: content_detail.data_source.type>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.url>, <TextNode: '" target="_blank">'>, <Variable Node: content_detail.data_source.url>, <TextNode: '</a></td>\n '>, <Variable Node: content_detail.data_source.description>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.weight>, <TextNode: '</td>\n '>]>} {'ticker': 'SAGE'}
components/footer.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/footer.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb55b1300>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55b1080>>'} {'content_detail': {'content': <Content: Sage Therapeutics Announces Second Quarter 2025 Financial Results - Unknown>, 'content_content': <ContentContent: Content ID: 7697812>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: Avanza>}, 'ticker': 'SAGE'} {'block': <Block Node: footer. Contents: [<TextNode: '\n '>, <IncludeNode: template=<FilterExpression '"components/footer.html"'>>, <TextNode: '\n '>]>}

Context processors

django.template.context_processors.csrf: Toggle context
{'csrf_token': <SimpleLazyObject: <function csrf.<locals>._get_val at 0x7f3fb55b1300>>}
django.template.context_processors.debug: Toggle context
{}
django.template.context_processors.request: Toggle context
{'request': <WSGIRequest: GET '/ticker/SAGE/content/12043415'>}
django.contrib.auth.context_processors.auth: Toggle context
{'user': <SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55b1080>>)}
django.contrib.messages.context_processors.messages: Toggle context
{'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/SAGE/content/12043415'>>, 'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30, 'ERROR': 40}}

Cache calls from 1 backend

Summary

Total calls	Total time	Cache hits	Cache misses
0	0 ms	0	0

Commands

add	get	set	get_or_set	touch	delete	clear	get_many	set_many	delete_many	has_key	incr	decr	incr_version	decr_version
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Signals

Signal	Receivers
class_prepared
connection_created	register_type_handlers
got_request_exception
m2m_changed
post_delete
post_init
post_migrate	create_permissions, create_contenttypes
post_save	create_initial_trade_position
pre_delete
pre_init
pre_migrate	inject_rename_contenttypes_operations
pre_save
request_finished	close_old_connections, close_caches, reset_urlconf
request_started	reset_queries, close_old_connections
setting_changed	reset_cache, clear_cache_handlers, update_installed_apps, update_connections_time_zone, clear_routers_cache, reset_template_engines, storages_changed, clear_serializers_cache, language_changed, localize_settings_changed, complex_setting_changed, root_urlconf_changed, static_storage_changed, static_finders_changed, form_renderer_changed, auth_password_validators_changed, user_model_swapped, update_toolbar_config, reset_hashers, Options.setting_changed, update_level_tags, uninstall_if_needed, clear_caches, StaticFilesStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties

Path	Location
.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/.DS_Store
grappelli/.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/.DS_Store
grappelli/js/grappelli.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.js
grappelli/js/jquery.grp_related_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_m2m.js
grappelli/js/jquery.grp_autocomplete_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_fk.js
grappelli/js/jquery.grp_autocomplete_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_generic.js
grappelli/js/jquery.grp_timepicker.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_timepicker.js
grappelli/js/jquery.grp_collapsible_group.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible_group.js
grappelli/js/jquery.grp_related_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_generic.js
grappelli/js/jquery.grp_related_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_fk.js
grappelli/js/jquery.grp_collapsible.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible.js
grappelli/js/grappelli.min.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.min.js
grappelli/js/jquery.grp_autocomplete_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_m2m.js
grappelli/js/jquery.grp_inline.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_inline.js
grappelli/images/spritesheet-1694777276.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/spritesheet-1694777276.png
grappelli/images/backgrounds/loading-small.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/loading-small.gif
grappelli/images/backgrounds/changelist-results.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/changelist-results.png
grappelli/images/backgrounds/ui-sortable-placeholder.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/ui-sortable-placeholder.png
grappelli/images/backgrounds/nav-grabber.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/nav-grabber.gif
grappelli/images/backgrounds/messagelist.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/messagelist.png
grappelli/images/icons/ui-datepicker-next.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/ui-datepicker-next.png
grappelli/images/icons/link-external-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-external-small_hover.png
grappelli/images/icons/tools-arrow-up-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-arrow-up-handler_hover.png
grappelli/images/icons/date-hierarchy-back.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/date-hierarchy-back.png
grappelli/images/icons/tools-delete-handler-predelete.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler-predelete.png
grappelli/images/icons/breadcrumbs-rtl.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs-rtl.png
grappelli/images/icons/datepicker_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/datepicker_hover.png
grappelli/images/icons/tools-trash-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-trash-handler_hover.png
grappelli/images/icons/selector-add-m2m-vertical_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/selector-add-m2m-vertical_hover.png
grappelli/images/icons/tools-related-remove-handler-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small_hover.png
grappelli/images/icons/sorted-descending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-descending.png
grappelli/images/icons/breadcrumbs_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs_hover.png
grappelli/images/icons/tools-viewsite-link_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-viewsite-link_hover.png
grappelli/images/icons/object-tools-add-link.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/object-tools-add-link.png
grappelli/images/icons/tools-related-edit-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-edit-handler-small-disabled.png
grappelli/images/icons/tools-related-remove-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small-disabled.png
grappelli/images/icons/sorted-ascending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-ascending.png
grappelli/images/icons/link-internal-rtl-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-internal-rtl-small_hover.png
grappelli/images/icons/pulldown-handler_selected.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/pulldown-handler_selected.png
grappelli/images/icons/tools-delete-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler_hover.png

Content Detail

Versions

Time

Resource usage

Browser timing

Settings from app.settings

Headers

Request headers

Response headers

WSGI environ

Request

View information

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

Static files (720 found, 2 used)

Static file paths

Static file apps

Static files

django.contrib.staticfiles.finders.AppDirectoriesFinder (720 files)

Templates (6 rendered)

Template path

Templates

Context processors

Cache calls from 1 backend

Summary

Commands

Signals